StatCounter

lunedì 27 maggio 2019

ESMO EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

IMMUNOTARGET Registry in Advanced NSCLC With Oncogenic Driver Alterations  
Patients with actionable tumour alterations should receive targeted therapies and chemotherapy before considering immunotherapy